You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
步長製藥(603858.SH):子公司生產注射用帕瑞昔布鈉獲藥品GMP符合性檢查結果
格隆匯 08-20 16:18

格隆匯8月20日丨步長製藥(603858.SH)公佈,公司近日獲悉全資子公司山東康愛製藥有限公司(“山東康愛”)獲得山東省食品藥品審評查驗中心簽發的《藥品GMP符合性檢查結果通知書》。

檢查範圍為製劑Ⅱ車間(凍乾粉針劑生產線)。主要生產品種為注射用帕瑞昔布鈉(20mg、40mg),用於手術後疼痛的短期治療。在決定使用選擇性環氧化酶-2(COX-2)抑制劑前,應評估患者的整體風險。

根據米內網數據查詢,2020年中國(城市公立,城市社區,縣級公立,鄉鎮衞生)樣本醫院年度銷售趨勢顯示,注射用帕瑞昔布鈉銷售額為21.98億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account